ASCO 2021 | Improving outcomes in HCC with immunotherapy
Arndt Vogel
• 11 Jun 2021
Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the extent of improved outcomes for patients with hepatocellular carcinoma (HCC) treated with immunotherapy, as well as ongoing Phase III studies further elucidating the optimal immunotherapeutic approaches in patients with HCC. This was discussed at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.
